Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
18 Luglio 2023 - 2:00PM
Business Wire
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the
“Company”), a technology-based company with a well-established
clinical diagnostic business and a therapeutic development
business, today announced that it will release its second quarter
2023 financial results before the market opens on Friday, August 4,
2023. Management will host a conference call for the investment
community the same day at 8:30 AM ET (5:30 AM PT) to discuss the
results and answer questions.
The call may be accessed through a live audio webcast on the
Investor Relations section of the company’s website,
http://ir.fulgentgenetics.com. An audio replay will be available at
the same location.
About Fulgent
Fulgent is a technology-based company with a well-established
clinical diagnostic business and a therapeutic development
business. Fulgent’s clinical diagnostic business offers molecular
diagnostic testing services, comprehensive genetic testing, and
high-quality anatomic pathology laboratory services designed to
provide physicians and patients with clinically actionable
diagnostic information to improve the quality of patient care.
Fulgent’s therapeutic development business is focused on developing
drug candidates for treating a broad range of cancers using a novel
nanoencapsulation and targeted therapy platform designed to improve
the therapeutic window and pharmacokinetic profile of new and
existing cancer drugs. The Company aims to transform from a genomic
diagnostic business into a fully integrated precision medicine
company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230718267891/en/
Investor Relations Contact: The Blueshirt Group Melanie
Solomon, melanie@blueshirtgroup.com
Grafico Azioni Fulgent Genetics (NASDAQ:FLGT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Fulgent Genetics (NASDAQ:FLGT)
Storico
Da Set 2023 a Set 2024